PT1943243E - Inibidores de cinase - Google Patents

Inibidores de cinase Download PDF

Info

Publication number: PT1943243E
Authority: PT; Portugal
Prior art keywords: methyl; pyridin; pyrazol; mmol; tolyl
Prior art date: 2005-10-28

Application number

PT06826650T

Other languages

English (en)

Portuguese (pt)

Inventor

Chuan Shih

Beatriz Lopez De Uralde Garmendia

Mary Margaret Mader

Alfonso De Dios

Tiechao Li

Mark Andrew Pobanz

Boyu Zhong

Michael Ray Myers

Jolie Anne Bastian

Jesus Andres Blas De Blas

Kevin John Hudziak

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-28

Filing date

2006-10-25

Publication date

2011-01-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43298635&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1943243(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-10-25 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2011-01-11 Publication of PT1943243E publication Critical patent/PT1943243E/pt

Links

229940043355 kinase inhibitor Drugs 0.000 title description 5
239000003757 phosphotransferase inhibitor Substances 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims description 225
-1 Phenyl- Chemical group 0.000 claims description 201
238000002360 preparation method Methods 0.000 claims description 91
239000004202 carbamide Substances 0.000 claims description 79
239000007787 solid Substances 0.000 claims description 75
238000000034 method Methods 0.000 claims description 71
150000003839 salts Chemical class 0.000 claims description 52
238000011282 treatment Methods 0.000 claims description 26
229910052739 hydrogen Inorganic materials 0.000 claims description 16
239000001257 hydrogen Substances 0.000 claims description 15
125000001424 substituent group Chemical group 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 14
125000000217 alkyl group Chemical group 0.000 claims description 13
239000000546 pharmaceutical excipient Substances 0.000 claims description 13
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 7
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
239000012230 colorless oil Substances 0.000 claims description 5
125000004076 pyridyl group Chemical group 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
125000001188 haloalkyl group Chemical group 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
125000001544 thienyl group Chemical group 0.000 claims description 3
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
150000002431 hydrogen Chemical group 0.000 claims description 2
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
125000001475 halogen functional group Chemical group 0.000 claims 5
101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 claims 2
101150035983 str1 gene Proteins 0.000 claims 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims 1
239000004744 fabric Substances 0.000 claims 1
240000004308 marijuana Species 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 215
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 179
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 103
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
239000000243 solution Substances 0.000 description 92
235000019439 ethyl acetate Nutrition 0.000 description 83
230000002829 reductive effect Effects 0.000 description 75
239000000203 mixture Substances 0.000 description 63
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
238000003756 stirring Methods 0.000 description 59
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 52
239000012141 concentrate Substances 0.000 description 49
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
235000008504 concentrate Nutrition 0.000 description 47
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 45
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
239000000741 silica gel Substances 0.000 description 41
229910002027 silica gel Inorganic materials 0.000 description 41
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 38
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 37
229910052938 sodium sulfate Inorganic materials 0.000 description 35
235000011152 sodium sulphate Nutrition 0.000 description 35
239000011541 reaction mixture Substances 0.000 description 34
239000002904 solvent Substances 0.000 description 34
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
239000012044 organic layer Substances 0.000 description 33
239000000284 extract Substances 0.000 description 31
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
229920006395 saturated elastomer Polymers 0.000 description 28
238000006243 chemical reaction Methods 0.000 description 25
238000010422 painting Methods 0.000 description 23
238000004519 manufacturing process Methods 0.000 description 22
241000124008 Mammalia Species 0.000 description 21
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 19
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 19
239000011780 sodium chloride Substances 0.000 description 19
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
206010028980 Neoplasm Diseases 0.000 description 17
210000004027 cell Anatomy 0.000 description 17
239000000460 chlorine Substances 0.000 description 17
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 16
102000004127 Cytokines Human genes 0.000 description 16
108090000695 Cytokines Proteins 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 16
241000700159 Rattus Species 0.000 description 16
229910052757 nitrogen Inorganic materials 0.000 description 16
239000003921 oil Substances 0.000 description 16
235000019198 oils Nutrition 0.000 description 16
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 16
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 15
238000005160 1H NMR spectroscopy Methods 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
108091000080 Phosphotransferase Proteins 0.000 description 14
102000020233 phosphotransferase Human genes 0.000 description 14
235000017557 sodium bicarbonate Nutrition 0.000 description 14
229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 13
230000002401 inhibitory effect Effects 0.000 description 13
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
239000000706 filtrate Substances 0.000 description 12
239000010410 layer Substances 0.000 description 12
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 12
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
239000007864 aqueous solution Substances 0.000 description 11
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
229910000041 hydrogen chloride Inorganic materials 0.000 description 11
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 11
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
239000002253 acid Substances 0.000 description 10
238000004587 chromatography analysis Methods 0.000 description 10
239000003085 diluting agent Substances 0.000 description 10
239000012074 organic phase Substances 0.000 description 10
239000000725 suspension Substances 0.000 description 10
229910052943 magnesium sulfate Inorganic materials 0.000 description 9
235000019341 magnesium sulphate Nutrition 0.000 description 9
239000000047 product Substances 0.000 description 9
239000011734 sodium Substances 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
238000001816 cooling Methods 0.000 description 8
125000005843 halogen group Chemical group 0.000 description 8
239000003112 inhibitor Substances 0.000 description 8
239000000843 powder Substances 0.000 description 8
229910021529 ammonia Inorganic materials 0.000 description 7
239000000872 buffer Substances 0.000 description 7
238000001914 filtration Methods 0.000 description 7
125000004438 haloalkoxy group Chemical group 0.000 description 7
238000000746 purification Methods 0.000 description 7
239000002002 slurry Substances 0.000 description 7
230000001629 suppression Effects 0.000 description 7
238000005406 washing Methods 0.000 description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 6
JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 6
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
150000001412 amines Chemical class 0.000 description 6
210000003423 ankle Anatomy 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
208000035269 cancer or benign tumor Diseases 0.000 description 6
239000003937 drug carrier Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000012458 free base Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 5
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
206010027476 Metastases Diseases 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
206010003246 arthritis Diseases 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000002585 base Substances 0.000 description 5
230000033228 biological regulation Effects 0.000 description 5
239000002775 capsule Substances 0.000 description 5
238000001514 detection method Methods 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000002158 endotoxin Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
229920006008 lipopolysaccharide Polymers 0.000 description 5
229910000027 potassium carbonate Inorganic materials 0.000 description 5
238000012360 testing method Methods 0.000 description 5
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 4
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
ORLCYMQZIPSODD-UHFFFAOYSA-N 1-chloro-2-[chloro(2,2,2-trichloroethoxy)phosphoryl]oxybenzene Chemical compound ClC1=CC=CC=C1OP(Cl)(=O)OCC(Cl)(Cl)Cl ORLCYMQZIPSODD-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
102000003777 Interleukin-1 beta Human genes 0.000 description 4
108090000193 Interleukin-1 beta Proteins 0.000 description 4
230000033115 angiogenesis Effects 0.000 description 4
239000006286 aqueous extract Substances 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
239000011324 bead Substances 0.000 description 4
239000007853 buffer solution Substances 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
JWVNPUBYKCSIKR-UHFFFAOYSA-N n,n-dimethylpyrimidin-5-amine Chemical compound CN(C)C1=CN=CN=C1 JWVNPUBYKCSIKR-UHFFFAOYSA-N 0.000 description 4
239000012071 phase Substances 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
229940083542 sodium Drugs 0.000 description 4
238000003828 vacuum filtration Methods 0.000 description 4
YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 3
QRHUZEVERIHEPT-UHFFFAOYSA-N 2,6-difluorobenzoyl chloride Chemical compound FC1=CC=CC(F)=C1C(Cl)=O QRHUZEVERIHEPT-UHFFFAOYSA-N 0.000 description 3
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
HWZUMEVIIGNXGM-UHFFFAOYSA-N 2-chloro-4-methyl-5-nitropyridine Chemical compound CC1=CC(Cl)=NC=C1[N+]([O-])=O HWZUMEVIIGNXGM-UHFFFAOYSA-N 0.000 description 3
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
239000002361 compost Substances 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000010828 elution Methods 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000005227 gel permeation chromatography Methods 0.000 description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
229940098779 methanesulfonic acid Drugs 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
210000003024 peritoneal macrophage Anatomy 0.000 description 3
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
230000009467 reduction Effects 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
239000000758 substrate Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
FCHLOXPIYQBWBX-UHFFFAOYSA-N (2,6-difluorophenyl)-[4-(3-methyl-5-nitropyridin-2-yl)piperazin-1-yl]methanone Chemical compound CC1=CC([N+]([O-])=O)=CN=C1N1CCN(C(=O)C=2C(=CC=CC=2F)F)CC1 FCHLOXPIYQBWBX-UHFFFAOYSA-N 0.000 description 2
XAMBIJWZVIZZOG-UHFFFAOYSA-N (4-methylphenyl)hydrazine Chemical compound CC1=CC=C(NN)C=C1 XAMBIJWZVIZZOG-UHFFFAOYSA-N 0.000 description 2
JZYBISHNZPRUFY-UHFFFAOYSA-N 1-(4-chloropyridin-2-yl)piperazine;hydrochloride Chemical compound Cl.ClC1=CC=NC(N2CCNCC2)=C1 JZYBISHNZPRUFY-UHFFFAOYSA-N 0.000 description 2
ICIRPSFBYLWIOK-UHFFFAOYSA-N 1-[2-[1-(2,6-difluorobenzoyl)piperidin-4-yl]oxypyridin-4-yl]-3-[5-(1,3-difluoro-2-methylpropan-2-yl)-2-(4-methylphenyl)pyrazol-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(OC3CCN(CC3)C(=O)C=3C(=CC=CC=3F)F)N=CC=2)=CC(C(C)(CF)CF)=N1 ICIRPSFBYLWIOK-UHFFFAOYSA-N 0.000 description 2
NYIGXLRPIIPZMK-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[5-methyl-6-[4-(1-methylcyclopropanecarbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(C)C(N3CCN(CC3)C(=O)C3(C)CC3)=NC=2)=CC(C(C)(C)C)=N1 NYIGXLRPIIPZMK-UHFFFAOYSA-N 0.000 description 2
MPHHUKLYPZEASP-UHFFFAOYSA-N 1-[5-tert-butyl-2-(6-methylpyridin-3-yl)pyrazol-3-yl]-3-[2-methyl-6-[4-(3-methylthiophene-2-carbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1=CSC(C(=O)N2CCN(CC2)C=2N=C(C)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=NC(C)=CC=3)=CC=2)=C1C MPHHUKLYPZEASP-UHFFFAOYSA-N 0.000 description 2
GJPFWAVDQOWRCV-UHFFFAOYSA-N 1-[6-[4-(2-chlorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]-3-[2-(6-methylpyridin-3-yl)-5-[1-(trifluoromethyl)cyclopropyl]pyrazol-3-yl]urea Chemical compound C1=NC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(=CC=2)N2CCN(CC2)C(=O)C=2C(=CC=CC=2)Cl)C)=CC(C2(CC2)C(F)(F)F)=N1 GJPFWAVDQOWRCV-UHFFFAOYSA-N 0.000 description 2
QIMMXZDDOJVSRT-UHFFFAOYSA-N 1-[6-[4-(2-fluorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]-3-[2-(6-methylpyridin-3-yl)-5-[1-(trifluoromethyl)cyclopropyl]pyrazol-3-yl]urea Chemical compound C1=NC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(=CC=2)N2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)C)=CC(C2(CC2)C(F)(F)F)=N1 QIMMXZDDOJVSRT-UHFFFAOYSA-N 0.000 description 2
125000006458 1-fluoromethyl cyclopropyl group Chemical group [H]C([H])(F)C1(*)C([H])([H])C1([H])[H] 0.000 description 2
XLPDVAVQKGDHNO-UHFFFAOYSA-N 2,3-dichloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CN=C(Cl)C(Cl)=C1 XLPDVAVQKGDHNO-UHFFFAOYSA-N 0.000 description 2
125000006334 2,4-difluoro benzoyl group Chemical group [H]C1=C([H])C(C(*)=O)=C(F)C([H])=C1F 0.000 description 2
ONOTYLMNTZNAQZ-UHFFFAOYSA-N 2,6-difluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=CC=C1F ONOTYLMNTZNAQZ-UHFFFAOYSA-N 0.000 description 2
KPRZOPQOBJRYSW-UHFFFAOYSA-N 2-(aminomethyl)phenol Chemical compound NCC1=CC=CC=C1O KPRZOPQOBJRYSW-UHFFFAOYSA-N 0.000 description 2
125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 description 2
IJODBPCRGUDNAW-UHFFFAOYSA-N 4,4,5,5,5-pentafluoro-3-oxopentanenitrile Chemical compound FC(F)(F)C(F)(F)C(=O)CC#N IJODBPCRGUDNAW-UHFFFAOYSA-N 0.000 description 2
OHZUEFKOZYWUFF-UHFFFAOYSA-N 4-hydroxypiperidine-1-carboxylic acid Chemical compound OC1CCN(C(O)=O)CC1 OHZUEFKOZYWUFF-UHFFFAOYSA-N 0.000 description 2
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
239000012826 P38 inhibitor Substances 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
CXQVHDKBKKZLMS-UHFFFAOYSA-N [4-(4-aminopyridin-2-yl)oxypiperidin-1-yl]-(2,6-difluorophenyl)methanone Chemical compound NC1=CC=NC(OC2CCN(CC2)C(=O)C=2C(=CC=CC=2F)F)=C1 CXQVHDKBKKZLMS-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000003092 anti-cytokine Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
239000012267 brine Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
238000012754 cardiac puncture Methods 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
239000012043 crude product Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
229960001760 dimethyl sulfoxide Drugs 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000000975 dye Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000010931 gold Substances 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
239000005457 ice water Substances 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
238000011694 lewis rat Methods 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002609 medium Substances 0.000 description 2
WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 2
PAWUSHZXEZPDBE-UHFFFAOYSA-N methyl 1-(trifluoromethyl)cyclopropane-1-carboxylate Chemical compound COC(=O)C1(C(F)(F)F)CC1 PAWUSHZXEZPDBE-UHFFFAOYSA-N 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229940127234 oral contraceptive Drugs 0.000 description 2
239000003539 oral contraceptive agent Substances 0.000 description 2
231100000822 oral exposure Toxicity 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 2
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000008279 sol Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
RMHRRMBFHGEDSR-UHFFFAOYSA-N tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)C=N1 RMHRRMBFHGEDSR-UHFFFAOYSA-N 0.000 description 2
DIHRSBUULWXMEV-UHFFFAOYSA-N tert-butyl 4-[(5-nitropyridin-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=C([N+]([O-])=O)C=N1 DIHRSBUULWXMEV-UHFFFAOYSA-N 0.000 description 2
PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 2
CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
WFDYOKBYDJIGLN-UHFFFAOYSA-N (2,6-difluorophenyl)-piperazin-1-ylmethanone Chemical compound FC1=CC=CC(F)=C1C(=O)N1CCNCC1 WFDYOKBYDJIGLN-UHFFFAOYSA-N 0.000 description 1
KJGFNDCSTWGUDT-UHFFFAOYSA-N (2-methylanilino)azanium;chloride Chemical compound Cl.CC1=CC=CC=C1NN KJGFNDCSTWGUDT-UHFFFAOYSA-N 0.000 description 1
NSMWYRLQHIXVAP-OLQVQODUSA-N (2r,5s)-2,5-dimethylpiperazine Chemical compound C[C@H]1CN[C@H](C)CN1 NSMWYRLQHIXVAP-OLQVQODUSA-N 0.000 description 1
OUWUZJDWCPZADV-UHFFFAOYSA-L (3-chlorophenyl) phosphate Chemical compound [O-]P([O-])(=O)OC1=CC=CC(Cl)=C1 OUWUZJDWCPZADV-UHFFFAOYSA-L 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
TVAFFJRJJNOFDU-UHFFFAOYSA-N 1,3-dihydrotetrazol-2-amine Chemical compound NN1NNC=N1 TVAFFJRJJNOFDU-UHFFFAOYSA-N 0.000 description 1
ASZBJMURURAMRZ-UHFFFAOYSA-N 1-(3-methyl-5-nitropyridin-2-yl)piperazine;hydrochloride Chemical compound Cl.CC1=CC([N+]([O-])=O)=CN=C1N1CCNCC1 ASZBJMURURAMRZ-UHFFFAOYSA-N 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
BSISXTCXCGSZJH-UHFFFAOYSA-N 1-[2-[1-(2,6-difluorobenzoyl)piperidin-4-yl]oxypyridin-4-yl]-3-[5-(1-fluoro-2-methylpropan-2-yl)-2-(4-methylphenyl)pyrazol-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(OC3CCN(CC3)C(=O)C=3C(=CC=CC=3F)F)N=CC=2)=CC(C(C)(C)CF)=N1 BSISXTCXCGSZJH-UHFFFAOYSA-N 0.000 description 1
COAFXJVOJIHFAD-UHFFFAOYSA-N 1-[2-[1-(2,6-difluorobenzoyl)piperidin-4-yl]oxypyridin-4-yl]-3-[5-[1-(fluoromethyl)cyclopropyl]-2-(4-methylphenyl)pyrazol-3-yl]urea Chemical compound FC1=C(C(=O)N2CCC(CC2)OC2=NC=CC(=C2)NC(=O)NC=2N(N=C(C=2)C2(CC2)CF)C2=CC=C(C=C2)C)C(=CC=C1)F COAFXJVOJIHFAD-UHFFFAOYSA-N 0.000 description 1
ZBGQBAVQAWJPRP-UHFFFAOYSA-N 1-[2-methyl-6-[4-(3-methylthiophene-2-carbonyl)piperazin-1-yl]pyridin-3-yl]-3-[2-(6-methylpyridin-3-yl)-5-[1-(trifluoromethyl)cyclopropyl]pyrazol-3-yl]urea Chemical compound C1=CSC(C(=O)N2CCN(CC2)C=2N=C(C)C(NC(=O)NC=3N(N=C(C=3)C3(CC3)C(F)(F)F)C=3C=NC(C)=CC=3)=CC=2)=C1C ZBGQBAVQAWJPRP-UHFFFAOYSA-N 0.000 description 1
QRICFWOGKSXSQQ-UHFFFAOYSA-N 1-[4-(5-amino-4-chloropyridin-2-yl)piperazin-1-yl]-2,2-dimethylpropan-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCN1C1=CC(Cl)=C(N)C=N1 QRICFWOGKSXSQQ-UHFFFAOYSA-N 0.000 description 1
ZHQKWARCNZEISX-UHFFFAOYSA-N 1-[4-(5-amino-4-methylpyridin-2-yl)piperazin-1-yl]-2,2-dimethylpropan-1-one Chemical compound C1=C(N)C(C)=CC(N2CCN(CC2)C(=O)C(C)(C)C)=N1 ZHQKWARCNZEISX-UHFFFAOYSA-N 0.000 description 1
DQLHAZICIUVBFI-UHFFFAOYSA-N 1-[4-[5-amino-3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-2,2-dimethylpropan-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCN1C1=NC=C(N)C=C1C(F)(F)F DQLHAZICIUVBFI-UHFFFAOYSA-N 0.000 description 1
IBHOVQDVOGIFLT-UHFFFAOYSA-N 1-[5-(1-methylcyclohexyl)-2-(4-methylphenyl)pyrazol-3-yl]-3-(5-methyl-6-piperazin-1-ylpyridin-3-yl)urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(C)C(N3CCNCC3)=NC=2)=CC(C2(C)CCCCC2)=N1 IBHOVQDVOGIFLT-UHFFFAOYSA-N 0.000 description 1
SSXNPMLRPYXWCX-UHFFFAOYSA-N 1-[5-(1-methylcyclopropyl)-2-(4-methylphenyl)pyrazol-3-yl]-3-(2-methyl-6-piperazin-1-ylpyridin-3-yl)urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(=CC=2)N2CCNCC2)C)=CC(C2(C)CC2)=N1 SSXNPMLRPYXWCX-UHFFFAOYSA-N 0.000 description 1
LTWASMDKSXJATO-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-(2-methyl-6-piperazin-1-ylpyridin-3-yl)urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(=CC=2)N2CCNCC2)C)=CC(C(C)(C)C)=N1 LTWASMDKSXJATO-UHFFFAOYSA-N 0.000 description 1
VMPSTYWHQCCQPJ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-(2-methyl-6-piperidin-4-yloxypyridin-3-yl)urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(OC3CCNCC3)=CC=2)C)=CC(C(C)(C)C)=N1 VMPSTYWHQCCQPJ-UHFFFAOYSA-N 0.000 description 1
JWINERHBLQTAHI-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-(2-piperidin-4-yloxypyridin-4-yl)urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(OC3CCNCC3)N=CC=2)=CC(C(C)(C)C)=N1 JWINERHBLQTAHI-UHFFFAOYSA-N 0.000 description 1
HKTMUIXMYNZTIR-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-(5-chloro-6-piperidin-4-yloxypyridin-3-yl)urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(Cl)C(OC3CCNCC3)=NC=2)=CC(C(C)(C)C)=N1 HKTMUIXMYNZTIR-UHFFFAOYSA-N 0.000 description 1
WYKITCGRMMAXBH-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-(6-piperazin-1-ylpyridin-3-yl)urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=NC(=CC=2)N2CCNCC2)=CC(C(C)(C)C)=N1 WYKITCGRMMAXBH-UHFFFAOYSA-N 0.000 description 1
POGJUJOYTYBYSX-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[2-methyl-6-[4-(pyridine-2-carbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(=CC=2)N2CCN(CC2)C(=O)C=2N=CC=CC=2)C)=CC(C(C)(C)C)=N1 POGJUJOYTYBYSX-UHFFFAOYSA-N 0.000 description 1
XZHZWQDVFFNBAA-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-methyl-6-[4-(1-methylcyclopropanecarbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=CC(=NC=2)N2CCN(CC2)C(=O)C2(C)CC2)C)=CC(C(C)(C)C)=N1 XZHZWQDVFFNBAA-UHFFFAOYSA-N 0.000 description 1
LDZKCLULLKYLLP-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[5-chloro-6-[4-(1-methylcyclopropanecarbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(Cl)C(N3CCN(CC3)C(=O)C3(C)CC3)=NC=2)=CC(C(C)(C)C)=N1 LDZKCLULLKYLLP-UHFFFAOYSA-N 0.000 description 1
QEBLUMVZCBIVRO-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[5-chloro-6-[4-(cyclopropanecarbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(Cl)C(N3CCN(CC3)C(=O)C3CC3)=NC=2)=CC(C(C)(C)C)=N1 QEBLUMVZCBIVRO-UHFFFAOYSA-N 0.000 description 1
NVXMXACYULRHEM-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[5-methyl-6-[1-(3-methylthiophene-2-carbonyl)piperidin-4-yl]oxypyridin-3-yl]urea Chemical compound C1=CSC(C(=O)N2CCC(CC2)OC=2C(=CC(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CN=2)C)=C1C NVXMXACYULRHEM-UHFFFAOYSA-N 0.000 description 1
IMOGWRHZMHXWTK-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[5-methyl-6-[4-(3-methylthiophene-2-carbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1=CSC(C(=O)N2CCN(CC2)C=2C(=CC(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CN=2)C)=C1C IMOGWRHZMHXWTK-UHFFFAOYSA-N 0.000 description 1
VCXZGXGCYUJTBX-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-(piperidin-4-ylamino)pyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=NC(NC3CCNCC3)=CC=2)=CC(C(C)(C)C)=N1 VCXZGXGCYUJTBX-UHFFFAOYSA-N 0.000 description 1
LPAUBUZUAIRZAK-FCHUYYIVSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[(2s,5r)-4-(cyclopropanecarbonyl)-2,5-dimethylpiperazin-1-yl]-5-methylpyridin-3-yl]urea Chemical compound C([C@H](C)N(C[C@H]1C)C=2C(=CC(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CN=2)C)N1C(=O)C1CC1 LPAUBUZUAIRZAK-FCHUYYIVSA-N 0.000 description 1
QJUFUVIUHCMARC-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxy-2-methylpyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(OC3CCN(CC3)C(=O)C=3C(=CC(F)=CC=3)F)=CC=2)C)=CC(C(C)(C)C)=N1 QJUFUVIUHCMARC-UHFFFAOYSA-N 0.000 description 1
BEHXWBHSQBJDHA-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxypyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=NC(OC3CCN(CC3)C(=O)C=3C(=CC(F)=CC=3)F)=CC=2)=CC(C(C)(C)C)=N1 BEHXWBHSQBJDHA-UHFFFAOYSA-N 0.000 description 1
IWFAXOKHKQUIDE-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[1-(2,5-dichlorothiophene-3-carbonyl)piperidin-4-yl]oxy-5-methylpyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(C)C(OC3CCN(CC3)C(=O)C3=C(SC(Cl)=C3)Cl)=NC=2)=CC(C(C)(C)C)=N1 IWFAXOKHKQUIDE-UHFFFAOYSA-N 0.000 description 1
KBMYFJGLQLFVEQ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[1-(2,6-difluorobenzoyl)piperidin-4-yl]oxy-2-methylpyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(OC3CCN(CC3)C(=O)C=3C(=CC=CC=3F)F)=CC=2)C)=CC(C(C)(C)C)=N1 KBMYFJGLQLFVEQ-UHFFFAOYSA-N 0.000 description 1
LUPOUSYEFLPEBF-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[1-(2,6-difluorobenzoyl)piperidin-4-yl]oxypyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=NC(OC3CCN(CC3)C(=O)C=3C(=CC=CC=3F)F)=CC=2)=CC(C(C)(C)C)=N1 LUPOUSYEFLPEBF-UHFFFAOYSA-N 0.000 description 1
URZAHJQXPQKZMZ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[1-(2-fluorobenzoyl)piperidin-4-yl]oxy-2-methylpyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(OC3CCN(CC3)C(=O)C=3C(=CC=CC=3)F)=CC=2)C)=CC(C(C)(C)C)=N1 URZAHJQXPQKZMZ-UHFFFAOYSA-N 0.000 description 1
QJNQTUFTKNCHLH-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[1-(3-methylthiophene-2-carbonyl)piperidin-4-yl]oxypyridin-3-yl]urea Chemical compound C1=CSC(C(=O)N2CCC(CC2)OC=2N=CC(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=C1C QJNQTUFTKNCHLH-UHFFFAOYSA-N 0.000 description 1
GVMCEODNQDVLKH-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[1-(cyclopropanecarbonyl)piperidin-4-yl]oxy-5-methylpyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(C)C(OC3CCN(CC3)C(=O)C3CC3)=NC=2)=CC(C(C)(C)C)=N1 GVMCEODNQDVLKH-UHFFFAOYSA-N 0.000 description 1
FISBPTFMXUIBSQ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(2,2,3,3-tetramethylcyclopropanecarbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(nc1)N1CCN(CC1)C(=O)C1C(C)(C)C1(C)C)C(C)(C)C FISBPTFMXUIBSQ-UHFFFAOYSA-N 0.000 description 1
SEQGWUCMRUZBJU-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-4-methylpyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=CC(=NC=2)N2CCN(CC2)C(=O)C(C)(C)C)C)=CC(C(C)(C)C)=N1 SEQGWUCMRUZBJU-UHFFFAOYSA-N 0.000 description 1
ZYHYUDMIHQRHCY-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-5-methylpyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(C)C(N3CCN(CC3)C(=O)C(C)(C)C)=NC=2)=CC(C(C)(C)C)=N1 ZYHYUDMIHQRHCY-UHFFFAOYSA-N 0.000 description 1
DKWXXSNHNBBZFP-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=NC(=CC=2)N2CCN(CC2)C(=O)C(C)(C)C)=CC(C(C)(C)C)=N1 DKWXXSNHNBBZFP-UHFFFAOYSA-N 0.000 description 1
SMLOFDCGLLNJPZ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(2,4-difluorobenzoyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(nc1)N1CCN(CC1)C(=O)c1ccc(F)cc1F)C(C)(C)C SMLOFDCGLLNJPZ-UHFFFAOYSA-N 0.000 description 1
PVXWUEAJWFLVTE-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(2,6-difluorobenzoyl)piperazin-1-yl]-5-methylpyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(C)C(N3CCN(CC3)C(=O)C=3C(=CC=CC=3F)F)=NC=2)=CC(C(C)(C)C)=N1 PVXWUEAJWFLVTE-UHFFFAOYSA-N 0.000 description 1
ICZWELSNDOMHBN-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(2,6-difluorobenzoyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=NC(=CC=2)N2CCN(CC2)C(=O)C=2C(=CC=CC=2F)F)=CC(C(C)(C)C)=N1 ICZWELSNDOMHBN-UHFFFAOYSA-N 0.000 description 1
CVQQAPYSCXUFDV-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(2-fluoro-6-methoxybenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]urea Chemical compound COC1=CC=CC(F)=C1C(=O)N1CCN(C=2N=C(C)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)CC1 CVQQAPYSCXUFDV-UHFFFAOYSA-N 0.000 description 1
WBCIVJABHIIIKM-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(2-fluorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(=CC=2)N2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)C)=CC(C(C)(C)C)=N1 WBCIVJABHIIIKM-UHFFFAOYSA-N 0.000 description 1
ZERKVGAMKJFHNC-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(3-methylpentanoyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1CN(C(=O)CC(C)CC)CCN1C(N=C1)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(C)C=C1 ZERKVGAMKJFHNC-UHFFFAOYSA-N 0.000 description 1
LLSRHZVYBXGPPJ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(3-methylthiophene-2-carbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C1=CSC(C(=O)N2CCN(CC2)C=2N=CC(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=C1C LLSRHZVYBXGPPJ-UHFFFAOYSA-N 0.000 description 1
XGXFHVDJHWFGQI-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(cyclopropanecarbonyl)piperazin-1-yl]-5-methylpyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=C(C)C(N3CCN(CC3)C(=O)C3CC3)=NC=2)=CC(C(C)(C)C)=N1 XGXFHVDJHWFGQI-UHFFFAOYSA-N 0.000 description 1
VMDQCEQYDUOCBB-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[4-(cyclopropanecarbonyl)piperazin-1-yl]pyridin-3-yl]urea Chemical compound C(C)(C)(C)C=1C=C(N(N=1)C1=CC=C(C=C1)C)NC(=O)NC=1C=NC(=CC=1)N1CCN(CC1)C(=O)C1CC1 VMDQCEQYDUOCBB-UHFFFAOYSA-N 0.000 description 1
RUONERXJFTWMJJ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[6-[[4-(2,6-difluorobenzoyl)piperidin-4-yl]amino]pyridin-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=NC(NC3(CCNCC3)C(=O)C=3C(=CC=CC=3F)F)=CC=2)=CC(C(C)(C)C)=N1 RUONERXJFTWMJJ-UHFFFAOYSA-N 0.000 description 1
URRNGWPSCYISHS-UHFFFAOYSA-N 1-[5-tert-butyl-2-(6-methylpyridin-3-yl)pyrazol-3-yl]-3-(2-methyl-6-piperazin-1-ylpyridin-3-yl)urea Chemical compound C1=NC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(=CC=2)N2CCNCC2)C)=CC(C(C)(C)C)=N1 URRNGWPSCYISHS-UHFFFAOYSA-N 0.000 description 1
HGYWPYAKJJOMDO-UHFFFAOYSA-N 1-[5-tert-butyl-2-(6-methylpyridin-3-yl)pyrazol-3-yl]-3-[6-[4-(2-chlorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]urea Chemical compound C1=NC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(=CC=2)N2CCN(CC2)C(=O)C=2C(=CC=CC=2)Cl)C)=CC(C(C)(C)C)=N1 HGYWPYAKJJOMDO-UHFFFAOYSA-N 0.000 description 1
COOXSOMHUBJOCS-UHFFFAOYSA-N 1-[6-[4-(1-methylcyclohexanecarbonyl)piperazin-1-yl]pyridin-3-yl]-3-[5-(1-methylcyclopropyl)-2-(4-methylphenyl)pyrazol-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C=NC(=CC=2)N2CCN(CC2)C(=O)C2(C)CCCCC2)=CC(C2(C)CC2)=N1 COOXSOMHUBJOCS-UHFFFAOYSA-N 0.000 description 1
FMMCWGPGZJSSCC-UHFFFAOYSA-N 1-[6-[4-(2,2-dimethylpentanoyl)piperazin-1-yl]pyridin-3-yl]-3-[5-(1-methylcyclopropyl)-2-(4-methylphenyl)pyrazol-3-yl]urea Chemical compound C1CN(C(=O)C(C)(C)CCC)CCN1C(N=C1)=CC=C1NC(=O)NC1=CC(C2(C)CC2)=NN1C1=CC=C(C)C=C1 FMMCWGPGZJSSCC-UHFFFAOYSA-N 0.000 description 1
YLFWREKOADYHOJ-UHFFFAOYSA-N 1-[6-[4-(2,6-difluorobenzoyl)piperazin-1-yl]pyridin-3-yl]-3-[2-(4-methylphenyl)-5-trimethylsilylpyrazol-3-yl]urea Chemical compound FC1=C(C(=O)N2CCN(CC2)C2=CC=C(C=N2)NC(=O)NC=2N(N=C(C2)[Si](C)(C)C)C2=CC=C(C=C2)C)C(=CC=C1)F YLFWREKOADYHOJ-UHFFFAOYSA-N 0.000 description 1
KPHYQWGKSTZREA-UHFFFAOYSA-N 1-fluorocyclohexane-1-carboxylic acid Chemical compound OC(=O)C1(F)CCCCC1 KPHYQWGKSTZREA-UHFFFAOYSA-N 0.000 description 1
125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
REHQLKUNRPCYEW-UHFFFAOYSA-N 1-methylcyclohexane-1-carboxylic acid Chemical compound OC(=O)C1(C)CCCCC1 REHQLKUNRPCYEW-UHFFFAOYSA-N 0.000 description 1
DIZKLZKLNKQFGB-UHFFFAOYSA-N 1-methylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(C)CC1 DIZKLZKLNKQFGB-UHFFFAOYSA-N 0.000 description 1
QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 1
125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
GGCGDTASYRLFIC-UHFFFAOYSA-N 2,2,2-trichloroethyl n-[2-(4-methylphenyl)-5-trimethylsilylpyrazol-3-yl]carbamate Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)OCC(Cl)(Cl)Cl)=CC([Si](C)(C)C)=N1 GGCGDTASYRLFIC-UHFFFAOYSA-N 0.000 description 1
LNOUWBNAVWYDNK-UHFFFAOYSA-N 2,2,2-trichloroethyl n-[5-(1-methylcyclopropyl)-2-(4-methylphenyl)pyrazol-3-yl]carbamate Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)OCC(Cl)(Cl)Cl)=CC(C2(C)CC2)=N1 LNOUWBNAVWYDNK-UHFFFAOYSA-N 0.000 description 1
IHZCTSTTYASSCL-UHFFFAOYSA-N 2,2,2-trichloroethyl n-[5-[1-(fluoromethyl)cyclopropyl]-2-(4-methylphenyl)pyrazol-3-yl]carbamate Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)OCC(Cl)(Cl)Cl)=CC(C2(CF)CC2)=N1 IHZCTSTTYASSCL-UHFFFAOYSA-N 0.000 description 1
YPAUICVBALDQPY-UHFFFAOYSA-N 2,2,2-trimethoxyacetic acid Chemical compound COC(OC)(OC)C(O)=O YPAUICVBALDQPY-UHFFFAOYSA-N 0.000 description 1
PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 description 1
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
DGADNPLBVRLJGD-UHFFFAOYSA-N 2,3-dihydroxy-2-methylpropanoic acid Chemical compound OCC(O)(C)C(O)=O DGADNPLBVRLJGD-UHFFFAOYSA-N 0.000 description 1
TYPVHTOETJVYIV-UHFFFAOYSA-N 2,4-dichloropyridine Chemical compound ClC1=CC=NC(Cl)=C1 TYPVHTOETJVYIV-UHFFFAOYSA-N 0.000 description 1
125000004098 2,6-dichlorobenzoyl group Chemical group O=C([*])C1=C(Cl)C([H])=C([H])C([H])=C1Cl 0.000 description 1
LVWWWVCVJOTNMC-UHFFFAOYSA-N 2-(4-methylphenyl)-5-(1,1,2,2,2-pentafluoroethyl)pyrazol-3-amine Chemical compound C1=CC(C)=CC=C1N1C(N)=CC(C(F)(F)C(F)(F)F)=N1 LVWWWVCVJOTNMC-UHFFFAOYSA-N 0.000 description 1
BWFIXSKSZJBXHN-UHFFFAOYSA-N 2-(4-methylphenyl)-5-[1-(trifluoromethyl)cyclopropyl]pyrazol-3-amine Chemical compound C1=CC(C)=CC=C1N1C(N)=CC(C2(CC2)C(F)(F)F)=N1 BWFIXSKSZJBXHN-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
OTZQYBFTOANOJO-UHFFFAOYSA-N 2-chloro-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1Cl OTZQYBFTOANOJO-UHFFFAOYSA-N 0.000 description 1
SOZDWBAAADDWHV-UHFFFAOYSA-N 2-chloro-2-nitro-1h-pyridine Chemical compound [O-][N+](=O)C1(Cl)NC=CC=C1 SOZDWBAAADDWHV-UHFFFAOYSA-N 0.000 description 1
LIEPVGBDUYKPLC-UHFFFAOYSA-N 2-chloro-4-nitropyridine Chemical compound [O-][N+](=O)C1=CC=NC(Cl)=C1 LIEPVGBDUYKPLC-UHFFFAOYSA-N 0.000 description 1
BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 1
KLEYVGWAORGTIT-UHFFFAOYSA-N 2-chlorothiazole Chemical compound ClC1=NC=CS1 KLEYVGWAORGTIT-UHFFFAOYSA-N 0.000 description 1
RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 description 1
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
CCFGTKQIRWHYTB-UHFFFAOYSA-N 2-methyl-3-nitropyridine Chemical compound CC1=NC=CC=C1[N+]([O-])=O CCFGTKQIRWHYTB-UHFFFAOYSA-N 0.000 description 1
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
PLAZTCDQAHEYBI-UHFFFAOYSA-N 2-nitrotoluene Chemical compound CC1=CC=CC=C1[N+]([O-])=O PLAZTCDQAHEYBI-UHFFFAOYSA-N 0.000 description 1
VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
KURLQFIJZCSUAJ-UHFFFAOYSA-N 3-methyl-5-nitro-2-piperidin-4-yloxypyridine Chemical compound CC1=CC([N+]([O-])=O)=CN=C1OC1CCNCC1 KURLQFIJZCSUAJ-UHFFFAOYSA-N 0.000 description 1
QLILRKBRWXALIE-UHFFFAOYSA-N 3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1 QLILRKBRWXALIE-UHFFFAOYSA-N 0.000 description 1
POHWEHXJRGNLOJ-UHFFFAOYSA-N 3-oxo-3-[1-(trifluoromethyl)cyclopropyl]propanenitrile Chemical compound N#CCC(=O)C1(C(F)(F)F)CC1 POHWEHXJRGNLOJ-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
JOLWWDNAIPHQLW-UHFFFAOYSA-N 4-nitro-2-piperidin-4-yloxypyridine Chemical compound [O-][N+](=O)C1=CC=NC(OC2CCNCC2)=C1 JOLWWDNAIPHQLW-UHFFFAOYSA-N 0.000 description 1
OWKOXJHTVNJOFP-UHFFFAOYSA-N 5,5,5-trifluoro-4-methyl-3-oxo-4-(trifluoromethyl)pentanenitrile Chemical compound FC(F)(F)C(C(F)(F)F)(C)C(=O)CC#N OWKOXJHTVNJOFP-UHFFFAOYSA-N 0.000 description 1
UXHKCMFKOVHGKT-UHFFFAOYSA-N 5-(1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl)-2-(4-methylphenyl)pyrazol-3-amine Chemical compound C1(=CC=C(C=C1)N1N=C(C=C1N)C(C(F)(F)F)(C(F)(F)F)C)C UXHKCMFKOVHGKT-UHFFFAOYSA-N 0.000 description 1
VQTFVTJRLJUIJR-UHFFFAOYSA-N 5-(1-methylcyclopropyl)-2-(6-methylpyridin-3-yl)pyrazol-3-amine Chemical compound C1=NC(C)=CC=C1N1C(N)=CC(C2(C)CC2)=N1 VQTFVTJRLJUIJR-UHFFFAOYSA-N 0.000 description 1
XKWSQIMYNVLGBO-UHFFFAOYSA-N 5-nitro-1h-pyridin-2-one Chemical compound OC1=CC=C([N+]([O-])=O)C=N1 XKWSQIMYNVLGBO-UHFFFAOYSA-N 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
240000004355 Borago officinalis Species 0.000 description 1
235000007689 Borago officinalis Nutrition 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
FURUKTKJKGFVKN-UHFFFAOYSA-N Br.Br.Br.Br.[Na] Chemical compound Br.Br.Br.Br.[Na] FURUKTKJKGFVKN-UHFFFAOYSA-N 0.000 description 1
XNMZBDDYINRGPN-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1C(CCCC1)OC1=NC=CC=C1 Chemical compound C(C)(C)(C)OC(=O)N1C(CCCC1)OC1=NC=CC=C1 XNMZBDDYINRGPN-UHFFFAOYSA-N 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
101100366466 Caenorhabditis elegans spo-11 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
102000000503 Collagen Type II Human genes 0.000 description 1
108010041390 Collagen Type II Proteins 0.000 description 1
102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
206010012218 Delirium Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
241000258963 Diplopoda Species 0.000 description 1
101100291385 Drosophila melanogaster p38a gene Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007821 HATU Substances 0.000 description 1
208000001688 Herpes Genitalis Diseases 0.000 description 1
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
101000973623 Homo sapiens Neuronal growth regulator 1 Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102100024065 Inhibitor of growth protein 1 Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102100039065 Interleukin-1 beta Human genes 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
239000004158 L-cystine Substances 0.000 description 1
235000019393 L-cystine Nutrition 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000018501 Lymphatic disease Diseases 0.000 description 1
206010027249 Meningitis meningococcal Diseases 0.000 description 1
201000010924 Meningococcal meningitis Diseases 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100059652 Mus musculus Cetn1 gene Proteins 0.000 description 1
101100059655 Mus musculus Cetn2 gene Proteins 0.000 description 1
101100232411 Mus musculus Clns1a gene Proteins 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
102100022223 Neuronal growth regulator 1 Human genes 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
GAZVSNAEUUUDEK-JDSLSITLSA-N [(1r,3r,4s)-4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl] 2-hydroxybenzoate Chemical compound O([C@H]1[C@@]2(C)CC[C@H](C1)C2(C)C)C(=O)C1=CC=CC=C1O GAZVSNAEUUUDEK-JDSLSITLSA-N 0.000 description 1
MGSCWWUCWYJCIK-NEPJUHHUSA-N [(2s,5r)-4-(5-amino-3-methylpyridin-2-yl)-2,5-dimethylpiperazin-1-yl]-cyclopropylmethanone Chemical compound C([C@@H](C)N(C[C@@H]1C)C=2C(=CC(N)=CN=2)C)N1C(=O)C1CC1 MGSCWWUCWYJCIK-NEPJUHHUSA-N 0.000 description 1
HHZXSXPKEKIPTO-UHFFFAOYSA-N [4-(5-amino-3-methylpyridin-2-yl)oxypiperidin-1-yl]-(2-fluorophenyl)methanone Chemical compound CC1=CC(N)=CN=C1OC1CCN(C(=O)C=2C(=CC=CC=2)F)CC1 HHZXSXPKEKIPTO-UHFFFAOYSA-N 0.000 description 1
LNUWQMRMBPZRMD-UHFFFAOYSA-N [4-(5-amino-3-methylpyridin-2-yl)piperazin-1-yl]-(2,6-difluorophenyl)methanone Chemical compound CC1=CC(N)=CN=C1N1CCN(C(=O)C=2C(=CC=CC=2F)F)CC1 LNUWQMRMBPZRMD-UHFFFAOYSA-N 0.000 description 1
PSDJWMOCNFJIIQ-UHFFFAOYSA-N [4-(5-amino-4-methylpyridin-2-yl)piperazin-1-yl]-(1-methylcyclopropyl)methanone Chemical compound C1=C(N)C(C)=CC(N2CCN(CC2)C(=O)C2(C)CC2)=N1 PSDJWMOCNFJIIQ-UHFFFAOYSA-N 0.000 description 1
HPMWTRNXJUENGD-UHFFFAOYSA-N [4-(5-amino-6-methylpyridin-2-yl)piperazin-1-yl]-(2,6-difluorophenyl)methanone Chemical compound C1=C(N)C(C)=NC(N2CCN(CC2)C(=O)C=2C(=CC=CC=2F)F)=C1 HPMWTRNXJUENGD-UHFFFAOYSA-N 0.000 description 1
MKHOQHPTBUPYEH-UHFFFAOYSA-N [5-(1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl)-2-(4-methylphenyl)pyrazol-3-yl]carbamic acid Chemical compound C1=CC(C)=CC=C1N1C(NC(O)=O)=CC(C(C)(C(F)(F)F)C(F)(F)F)=N1 MKHOQHPTBUPYEH-UHFFFAOYSA-N 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Substances CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000005276 aerator Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
KZTZJUQNSSLNAG-UHFFFAOYSA-N aminoethyl nitrate Chemical compound NCCO[N+]([O-])=O KZTZJUQNSSLNAG-UHFFFAOYSA-N 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
PLZZXRKTRWITII-UHFFFAOYSA-N benzyl 3-hydroxy-2,2-dimethylpropanoate Chemical compound OCC(C)(C)C(=O)OCC1=CC=CC=C1 PLZZXRKTRWITII-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
BHKTVMNUHSVTFH-UHFFFAOYSA-N carbamic acid;1h-pyrazole Chemical class NC(O)=O.C=1C=NNC=1 BHKTVMNUHSVTFH-UHFFFAOYSA-N 0.000 description 1
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000004568 cement Substances 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
239000012069 chiral reagent Substances 0.000 description 1
HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
229940125851 compound 27 Drugs 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
229960005168 croscarmellose Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000012351 deprotecting agent Substances 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical class CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
VDOLMNJREJLNBA-UHFFFAOYSA-N ethyl 1-(fluoromethyl)cyclopropane-1-carboxylate Chemical compound CCOC(=O)C1(CF)CC1 VDOLMNJREJLNBA-UHFFFAOYSA-N 0.000 description 1
FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000011888 foil Substances 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001879 gelation Methods 0.000 description 1
201000004946 genital herpes Diseases 0.000 description 1
ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
238000009499 grossing Methods 0.000 description 1
229920005555 halobutyl Polymers 0.000 description 1
125000004968 halobutyl group Chemical group 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
239000011654 magnesium acetate Substances 0.000 description 1
235000011285 magnesium acetate Nutrition 0.000 description 1
229940069446 magnesium acetate Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
AFCCDDWKHLHPDF-UHFFFAOYSA-M metam-sodium Chemical compound [Na+].CNC([S-])=S AFCCDDWKHLHPDF-UHFFFAOYSA-M 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
NKZISBBWNQEPAH-UHFFFAOYSA-N methyl 1-methylcyclohexane-1-carboxylate Chemical compound COC(=O)C1(C)CCCCC1 NKZISBBWNQEPAH-UHFFFAOYSA-N 0.000 description 1
COHFTBWCEOBGOR-UHFFFAOYSA-N methyl 1-methylcyclopropane-1-carboxylate Chemical compound COC(=O)C1(C)CC1 COHFTBWCEOBGOR-UHFFFAOYSA-N 0.000 description 1
CNXPCACWKXHRDD-UHFFFAOYSA-N methyl 2-(4-methylphenyl)-5-trimethylsilylpyrazole-3-carboxylate Chemical compound COC(=O)C1=CC([Si](C)(C)C)=NN1C1=CC=C(C)C=C1 CNXPCACWKXHRDD-UHFFFAOYSA-N 0.000 description 1
HQCNSTMROSOXCS-UHFFFAOYSA-N methyl 2-methyl-2,3-bis(trifluoromethylsulfonyloxy)propanoate Chemical compound FC(F)(F)S(=O)(=O)OC(C)(C(=O)OC)COS(=O)(=O)C(F)(F)F HQCNSTMROSOXCS-UHFFFAOYSA-N 0.000 description 1
IFFNDNZRDKTJEH-UHFFFAOYSA-N methyl 3-fluoro-2-(fluoromethyl)-2-methylpropanoate Chemical compound COC(=O)C(C)(CF)CF IFFNDNZRDKTJEH-UHFFFAOYSA-N 0.000 description 1
RQEPEDPOJQCJJT-UHFFFAOYSA-N methyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate Chemical compound COC(=O)C(C)(CO)CO RQEPEDPOJQCJJT-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
229940012189 methyl orange Drugs 0.000 description 1
229940017219 methyl propionate Drugs 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 1
150000002828 nitro derivatives Chemical class 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
229910000069 nitrogen hydride Inorganic materials 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002892 organic cations Chemical class 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000008723 osmotic stress Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
239000003973 paint Substances 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
229910052655 plagioclase feldspar Inorganic materials 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
229940066263 prednisolone 10 mg Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
IXRIKXJQFYIWSW-UHFFFAOYSA-N propan-1-one Chemical compound CC[C+]=O IXRIKXJQFYIWSW-UHFFFAOYSA-N 0.000 description 1
YYVGYULIMDRZMJ-UHFFFAOYSA-N propan-2-ylsilane Chemical compound CC(C)[SiH3] YYVGYULIMDRZMJ-UHFFFAOYSA-N 0.000 description 1
RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000004080 punching Methods 0.000 description 1
238000010926 purge Methods 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Natural products OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 1
239000010453 quartz Substances 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000004044 response Effects 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000004576 sand Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
229910000342 sodium bisulfate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
229960002218 sodium chlorite Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
229940046307 sodium thioglycolate Drugs 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
238000005476 soldering Methods 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000035882 stress Effects 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
PGZCVLUQTJRRAA-BDAKNGLRSA-N tert-butyl (2s,5r)-2,5-dimethylpiperazine-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)[C@@H](C)CN1 PGZCVLUQTJRRAA-BDAKNGLRSA-N 0.000 description 1
DIRGHALJXWVVHI-UHFFFAOYSA-N tert-butyl 2-(5-aminopyridin-2-yl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1C1=CC=C(N)C=N1 DIRGHALJXWVVHI-UHFFFAOYSA-N 0.000 description 1
RVXSTWGJVGAJLH-UHFFFAOYSA-N tert-butyl 4-(3-methyl-5-nitropyridin-2-yl)oxypiperidine-1-carboxylate Chemical compound CC1=CC([N+]([O-])=O)=CN=C1OC1CCN(C(=O)OC(C)(C)C)CC1 RVXSTWGJVGAJLH-UHFFFAOYSA-N 0.000 description 1
KNRISJJPNDQGGT-UHFFFAOYSA-N tert-butyl 4-(3-methyl-5-nitropyridin-2-yl)piperazine-1-carboxylate Chemical compound CC1=CC([N+]([O-])=O)=CN=C1N1CCN(C(=O)OC(C)(C)C)CC1 KNRISJJPNDQGGT-UHFFFAOYSA-N 0.000 description 1
ILEDGRIPSHSTFF-UHFFFAOYSA-N tert-butyl 4-(4-aminopyridin-2-yl)oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(N)=CC=N1 ILEDGRIPSHSTFF-UHFFFAOYSA-N 0.000 description 1
MGJJWQPUNAQTLI-UHFFFAOYSA-N tert-butyl 4-(5-amino-3-chloropyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=NC=C(N)C=C1Cl MGJJWQPUNAQTLI-UHFFFAOYSA-N 0.000 description 1
KTOPEZPRNKTBTG-UHFFFAOYSA-N tert-butyl 4-(5-amino-3-methylpyridin-2-yl)oxypiperidine-1-carboxylate Chemical compound CC1=CC(N)=CN=C1OC1CCN(C(=O)OC(C)(C)C)CC1 KTOPEZPRNKTBTG-UHFFFAOYSA-N 0.000 description 1
ONQPIGOFZAILRN-UHFFFAOYSA-N tert-butyl 4-(5-amino-3-methylpyridin-2-yl)piperazine-1-carboxylate Chemical compound CC1=CC(N)=CN=C1N1CCN(C(=O)OC(C)(C)C)CC1 ONQPIGOFZAILRN-UHFFFAOYSA-N 0.000 description 1
BOXAHUAQPAALSL-UHFFFAOYSA-N tert-butyl 4-(5-amino-6-methylpyridin-2-yl)oxypiperidine-1-carboxylate Chemical compound C1=C(N)C(C)=NC(OC2CCN(CC2)C(=O)OC(C)(C)C)=C1 BOXAHUAQPAALSL-UHFFFAOYSA-N 0.000 description 1
NZULECSKRTWAPX-UHFFFAOYSA-N tert-butyl 4-(5-amino-6-methylpyridin-2-yl)piperazine-1-carboxylate Chemical compound C1=C(N)C(C)=NC(N2CCN(CC2)C(=O)OC(C)(C)C)=C1 NZULECSKRTWAPX-UHFFFAOYSA-N 0.000 description 1
HPFXDGOQARRWGK-UHFFFAOYSA-N tert-butyl 4-(5-aminopyridin-2-yl)oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=C(N)C=N1 HPFXDGOQARRWGK-UHFFFAOYSA-N 0.000 description 1
WWFJYZONBJARJT-UHFFFAOYSA-N tert-butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C([N+]([O-])=O)C=N1 WWFJYZONBJARJT-UHFFFAOYSA-N 0.000 description 1
DUVNYIXNOISKEC-UHFFFAOYSA-N tert-butyl 4-(6-methyl-5-nitropyridin-2-yl)piperazine-1-carboxylate Chemical compound C1=C([N+]([O-])=O)C(C)=NC(N2CCN(CC2)C(=O)OC(C)(C)C)=C1 DUVNYIXNOISKEC-UHFFFAOYSA-N 0.000 description 1
FQTYGHIEYTTWFB-UHFFFAOYSA-N tert-butyl 4-[(5-aminopyridin-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=C(N)C=N1 FQTYGHIEYTTWFB-UHFFFAOYSA-N 0.000 description 1
QWHKFICSLAQGON-UHFFFAOYSA-N tert-butyl 4-[5-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]-6-methylpyridin-2-yl]piperazine-1-carboxylate Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(=CC=2)N2CCN(CC2)C(=O)OC(C)(C)C)C)=CC(C(C)(C)C)=N1 QWHKFICSLAQGON-UHFFFAOYSA-N 0.000 description 1
ONXXEZNQEQYNSP-UHFFFAOYSA-N tert-butyl 4-[6-methyl-5-[[5-(1-methylcyclopropyl)-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]pyridin-2-yl]piperazine-1-carboxylate Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C(=NC(=CC=2)N2CCN(CC2)C(=O)OC(C)(C)C)C)=CC(C2(C)CC2)=N1 ONXXEZNQEQYNSP-UHFFFAOYSA-N 0.000 description 1
LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
239000010930 yellow gold Substances 0.000 description 1
229910001097 yellow gold Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT06826650T 2005-10-28 2006-10-25 Inibidores de cinase PT1943243E (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US73160405P	2005-10-28	2005-10-28
EP06380151		2006-06-02
US82196306P	2006-08-10	2006-08-10

Publications (1)

Publication Number	Publication Date
PT1943243E true PT1943243E (pt)	2011-01-11

Family

ID=43298635

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT06826650T PT1943243E (pt)	2005-10-28	2006-10-25	Inibidores de cinase

Country Status (19)

Country	Link
US (1)	US7652015B2 (da)
EP (1)	EP1943243B1 (da)
KR (1)	KR101004156B1 (da)
AR (1)	AR056582A1 (da)
AT (1)	ATE493403T1 (da)
AU (1)	AU2006309044B2 (da)
BR (1)	BRPI0616901A2 (da)
CA (1)	CA2627673A1 (da)
DK (1)	DK1943243T3 (da)
DO (1)	DOP2006000234A (da)
EA (1)	EA015189B1 (da)
PE (1)	PE20070795A1 (da)
PL (1)	PL1943243T3 (da)
PT (1)	PT1943243E (da)
RS (1)	RS51949B (da)
SI (1)	SI1943243T1 (da)
TN (1)	TNSN08191A1 (da)
TW (1)	TWI325423B (da)
WO (1)	WO2007053394A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0905955D0 (en)	2009-04-06	2009-05-20	Respivert Ltd	Novel compounds
EP2556068B1 (en)	2010-04-08	2019-01-23	Respivert Limited	P38 map kinase inhibitors
WO2011158044A2 (en)	2010-06-17	2011-12-22	Respivert Limited	Respiratory formulations and compounds for use therein
AU2012289254A1 (en)	2011-07-26	2014-03-13	Grünenthal GmbH	Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands
WO2014033446A1 (en)	2012-08-29	2014-03-06	Respivert Limited	Kinase inhibitors
EP2890695A2 (en)	2012-08-29	2015-07-08	Respivert Limited	Kinase inhibitors
WO2014033449A1 (en)	2012-08-29	2014-03-06	Respivert Limited	Kinase inhibitors
EP2925742B1 (en)	2012-11-16	2016-10-26	Respivert Limited	Kinase inhibitors
US9771353B2 (en)	2013-04-02	2017-09-26	Topivert Pharma Limited	Kinase inhibitors based upon N-alkyl pyrazoles
CN105246884B (zh)	2013-04-02	2018-05-22	瑞斯比维特有限公司	用作激酶抑制剂的脲衍生物
JP6514703B2 (ja)	2013-12-20	2019-05-15	トピバートファーマリミテッド	キナーゼインヒビターとして有用な尿素誘導体
EP4180424A1 (en)	2014-03-07	2023-05-17	BioCryst Pharmaceuticals, Inc.	Substituted pyrazoles as human plasma kallikrein inhibitors
MA40774A (fr)	2014-10-01	2017-08-08	Respivert Ltd	Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
KR102387073B1 (ko)	2016-04-06	2022-04-15	옥슬러 액퀴지션즈 리미티드	키나제 저해제
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
SG10202110259QA (en)	2017-10-05	2021-10-28	Fulcrum Therapeutics Inc	Use of p38 inhibitors to reduce expression of dux4
PT3786160T (pt)	2017-10-27	2022-08-19	Boehringer Ingelheim Int	Derivados de piridina e suas utilizações terapêuticas como inibidores de trpc6

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2155817T3 (es) *	1997-12-22	2007-06-16	Bayer Pharmaceuticals Corp.	Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
ES2308523T3 (es) *	2004-06-23	2008-12-01	Eli Lilly And Company	Inhibidores de quinasa.

2006
- 2006-10-20 PE PE2006001275A patent/PE20070795A1/es not_active Application Discontinuation
- 2006-10-20 AR ARP060104595A patent/AR056582A1/es unknown
- 2006-10-20 TW TW095138670A patent/TWI325423B/zh not_active IP Right Cessation
- 2006-10-20 DO DO2006000234A patent/DOP2006000234A/es unknown
- 2006-10-25 BR BRPI0616901-5A patent/BRPI0616901A2/pt not_active IP Right Cessation
- 2006-10-25 EA EA200801199A patent/EA015189B1/ru not_active IP Right Cessation
- 2006-10-25 CA CA002627673A patent/CA2627673A1/en not_active Abandoned
- 2006-10-25 RS RS20110112A patent/RS51949B/en unknown
- 2006-10-25 PT PT06826650T patent/PT1943243E/pt unknown
- 2006-10-25 SI SI200630950T patent/SI1943243T1/sl unknown
- 2006-10-25 PL PL06826650T patent/PL1943243T3/pl unknown
- 2006-10-25 WO PCT/US2006/041644 patent/WO2007053394A1/en active Application Filing
- 2006-10-25 KR KR1020087010062A patent/KR101004156B1/ko not_active IP Right Cessation
- 2006-10-25 EP EP06826650A patent/EP1943243B1/en active Active
- 2006-10-25 US US12/088,526 patent/US7652015B2/en not_active Expired - Fee Related
- 2006-10-25 AT AT06826650T patent/ATE493403T1/de active
- 2006-10-25 AU AU2006309044A patent/AU2006309044B2/en not_active Expired - Fee Related
- 2006-10-25 DK DK06826650.1T patent/DK1943243T3/da active
2008
- 2008-04-25 TN TNP2008000191A patent/TNSN08191A1/en unknown

Also Published As

Publication number	Publication date
TNSN08191A1 (en)	2009-10-30
RS51949B (en)	2012-02-29
BRPI0616901A2 (pt)	2011-07-05
EP1943243A1 (en)	2008-07-16
US20080269244A1 (en)	2008-10-30
EP1943243B1 (en)	2010-12-29
WO2007053394A1 (en)	2007-05-10
DOP2006000234A (es)	2007-05-31
CA2627673A1 (en)	2007-05-10
KR20080053394A (ko)	2008-06-12
SI1943243T1 (sl)	2011-04-29
KR101004156B1 (ko)	2010-12-27
TWI325423B (en)	2010-06-01
AR056582A1 (es)	2007-10-10
EA015189B1 (ru)	2011-06-30
PL1943243T3 (pl)	2011-05-31
US7652015B2 (en)	2010-01-26
DK1943243T3 (da)	2011-03-07
AU2006309044B2 (en)	2011-10-13
PE20070795A1 (es)	2007-08-24
ATE493403T1 (de)	2011-01-15
AU2006309044A1 (en)	2007-05-10
TW200800184A (en)	2008-01-01
EA200801199A1 (ru)	2008-08-29

Publication	Publication Date	Title
PT1943243E (pt)	2011-01-11	Inibidores de cinase
US11945805B2 (en)	2024-04-02	Inhibitors of CXCR2
EP3390389B1 (en)	2021-05-19	Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
EP1761520B1 (en)	2008-07-09	Kinase inhibitors
ES2966772T3 (es)	2024-04-24	Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2H-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida
BR112017013806B1 (pt)	2023-03-28	Composto, composição farmacêutica, uso de um composto de fórmula (i) e processo para a fabricação de um composto
RU2468026C2 (ru)	2012-11-27	Производные пуринила и их применение в качестве модуляторов калиевых каналов
AU2006309174B2 (en)	2011-10-13	Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
PT1689751E (pt)	2010-11-29	Novas 5,7-diaminopirazolo[4,3-d]pirimidinas com actividade inibidora de pde-5
EP1824829B1 (en)	2010-05-05	3-substituted pyridine derivatives as h3 antagonists
WO2005028467A1 (en)	2005-03-31	Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
JP2007055940A (ja)	2007-03-08	ピラゾロピリミジン誘導体
EP2780331B1 (en)	2016-04-20	Pharmaceutically active pyrazine derivatives
CA3174829A1 (en)	2021-10-21	Pyrrolo[1,2-d][1,2,4]triazine-2-yl-acetamides as inhibitors of the nlrp3 inflammasome pathway
AU2020200840A1 (en)	2020-02-27	Pyrimidine compositions, ultra-pure compositions and salts thereof, methods of making the same, and methods of using the same for treating histamine H4 receptor (H4) mediated diseases and conditions
WO2019011228A1 (zh)	2019-01-17	咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
JP2007217408A (ja)	2007-08-30	医薬組成物
AU2020342189A1 (en)	2022-03-31	3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
WO1996028447A1 (fr)	1996-09-19	Derives de pyrrolocarbazole
JP7118347B2 (ja)	2022-08-16	重水素化（ｓ）２－（４－（ピペリジン－３－イル）フェニル）－２ｈ－インダゾール－７－カルボキサミド
CA3063180A1 (en)	2018-11-15	Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2021004482A1 (zh)	2021-01-14	取代的吡唑并喹唑啉酮化合物及其应用
ES2356133T3 (es)	2011-04-05	Inhibidores de cinasa.
CA3149883A1 (en)	2021-03-18	Substituted imidazoquinoxaline compounds and uses thereof
US20230271956A1 (en)	2023-08-31	Amide derivatives